August 1st Week, 2026 Regulatory Events 🎯 The US FDA granted a Type C Statistical Methods Meeting to OS Therapies to review the 2.5yrs OS data from the Ph2b trial of daznelimgene lisbac (OST-HER2; HER2 targeted immunotherapy vaccine) in the prevention of recurrence in fully resected, pulmonary metastatic osteosarcoma (Ref) ❓ How is OST-HER2 positioned in the osteosarcoma developmental landscape? Special Designations ⭐ The US FDA granted a Fast Track Designation to Gran